The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
BACKGROUND
To study the effect of the interval between surgery and the start of chemotherapy in the treatment of patients with advanced ovarian cancer.


METHODS
We stratified patients according to the start of platinum-based chemotherapy in group 1 (within 4 weeks from surgery), group 2 (between 4 and 8 weeks) and group 3 (between 8 and 12 weeks).


RESULTS
Three hundred and ninty-four stage III ovarian cancer patients were analysed. In the multivariate analysis there were no differences in survival according to the interval between surgery and chemotherapy among the three groups. The independent prognostic variables were type of procedure (p = 0.014), performance status (p = 0.040) and post-chemotherapy CA-125 (p < 0.0001).


CONCLUSIONS
The interval between surgery and chemotherapy does not affect outcome.
Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester. dornellesrosa@hotmail.com
D D
DD
Rosa
A
A
Clamp
S
S
Mullamitha
N C
NC
Ton
S
S
Lau
L
L
Byrd
R
R
Clayton
R J
RJ
Slade
H C
HC
Kitchener
J H
JH
Shanks
G
G
Wilson
R
R
McVey
J
J
Hasan
R
R
Swindell
G C
GC
Jayson
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018394:CA-125 Antigen / Q000032:analysis; D016190:Carboplatin / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D005187:Fallopian Tubes / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D008875:Middle Aged; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000473:pathology; D009852:Omentum / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000601:surgery*; D010052:Ovariectomy; D017671:Platinum Compounds / Q000627:therapeutic use; D011379:Prognosis; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D018394:CA-125 Antigen; D017671:Platinum Compounds; D016190:Carboplatin